Pneumococcal Vaccine Recommendations: Adults ages 19-64 years (2022)

The CDC recommends pneumococcal vaccination for adults 19-64 years old with certain underlying medical conditions¹ ² or other risk factors¹ ² or who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.

Have you ever received a pneumococcal vaccine (PCV13 and/or PPSV23)?

- **YES**
  - Which pneumococcal vaccine(s) did you receive?
    - Both PCV13 and PPSV23
      - If you have an immunocompromising condition¹
        - Previously received 1 dose of PPSV23
      - If you have a cerebrospinal fluid leak or cochlear implant²
        - Previously received 2 doses of PPSV23
    - Pneumococcal vaccine series complete until age 65!
    - Administer 2nd dose of PPSV23³ at least 8 weeks after PCV13 and at least 5 years after PPSV23.
    - Administer 1 dose of PCV15 OR PCV20.
      - If PCV15 is used, follow with 1 dose of PPSV23 at least 1 year later (minimum of 8 weeks) to complete the patient’s recommended pneumococcal vaccination series.

- **NO**
  - Pneumococcal vaccine series complete!
  - Administer 1 dose of PCV15 OR PCV20.
  - If PCV15 is used, follow with 1 dose of PPSV23 at least 1 year later (minimum of 8 weeks) to complete the patient’s recommended pneumococcal vaccination series.

- Only PPSV23
  - Administer 1 dose of PCV15 OR PCV20 at least 1 year after the last PPSV23 dose.

- Only PCV13
  - If you have an immunocompromising condition¹
    - Administer 2 additional doses of PPSV23³. Dose 1 at least 8 weeks after PCV13³. Dose 2 at least 5 years after PPSV23.
  - If you have a cerebrospinal fluid leak or cochlear implant²
    - Administer 1 dose⁴ of PPSV23³ at least 8 weeks after your last dose of PCV13.
Pneumococcal Vaccine Recommendations: Adults ages 19-64 years (2022)

The CDC recommends pneumococcal vaccination for adults 19-64 years old with certain underlying medical conditions\(^1\) \(^2\) or other risk factors\(^1\) \(^2\) or who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.

1) Immunocompromising conditions include:
- Chronic renal failure
- Nephrotic syndrome
- Congenital or acquired immunodeficiency (including B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease))
- Iatrogenic immunosuppression (including diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy)
- Generalized malignancy
- Human immunodeficiency virus (HIV)
- Hodgkin disease
- Leukemia
- Lymphoma
- Multiple myeloma
- Solid organ transplants
- Congenital or acquired asplenia
- Sickle cell disease
- Other hemoglobinopathies

2) Underlying medical conditions or other risk factors include:
- Alcoholism
- Chronic heart disease (including congestive heart failure and cardiomyopathies)
- Chronic liver disease
- Chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma)
- Cigarette smoking
- Diabetes mellitus
- Cochlear implant
- Cerebrospinal fluid leak

3) Adults ages 19-64 years with an immunocompromising condition who previously received only PCV13:
- The CDC recommends 2 doses of PPSV23 before age 65 years and 1 dose of PPSV23 at age 65 years or older.
- Administer a single dose of PPSV23 at least 8 weeks after PCV13 was received.
  - If the patient was younger than 65 years old when the first dose of PPSV23 was given and has not turned 65 years old yet, administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23. This is the last dose of PPSV23 that should be given prior to 65 years of age.
  - Once the patient turns 65 years old and at least 5 years have passed since PPSV23 was last given, administer a final dose of PPSV23 to complete their pneumococcal vaccinations.

4) Adults ages 19-64 years with a cerebrospinal fluid leak or cochlear implant who previously received only PCV13:
- The CDC recommends 1 dose of PPSV23 before age 65 years and 1 dose of PPSV23 at age 65 years or older.
- Administer a single dose of PPSV23 at least 8 weeks after PCV13 was received.
  - If the adult is 65 years or older, their pneumococcal vaccinations are complete.
  - If the adult was younger than 65 years old when the first dose of PPSV23 was given, then administer a final dose of PPSV23 once they turn 65 years old and when at least 5 years have passed since PPSV23 was first given. Then, their pneumococcal vaccinations are complete.

5) One dose of PCV20 may be used if PPSV23 is not available. If PCV20 is used, the patient's pneumococcal vaccinations are still considered complete.

The PneumoRecs VaxAdvisor mobile app helps vaccination providers quickly and easily determine which pneumococcal vaccines a patient needs and when. The app incorporates recommendations for all ages so internists, family physicians, pediatricians, and pharmacists alike will find the tool beneficial. The app provides patient-specific guidance consistent with the immunization schedule recommended by the U.S. Advisory Committee on Immunization Practices (ACIP). Download the App Today!

For more information regarding pneumococcal vaccination for adults please refer to the CDC Pneumococcal Vaccination webpage or the 2022 CDC Adult Immunization Schedule webpage. If you have questions regarding immunizations please contact the North Dakota Department of Health at 701-328-2372.